AbolerIS Pharma ("AbolerIS"), a clinical-stage biopharmaceutical company committed to improving the lives of people suffering from autoimmune and inflammatory diseases, announced today that the first ...

Antibodies are a critical feature of the human adaptive immune response. New immunotherapies require the production of selective and non-autoimmunogenic antibodies. These engineered antibodies can ...

In a recent study published on the medRxiv* preprint server, researchers combined severe acute respiratory syndrome coronavirus (SARS-CoV-2) spike receptor-binding domain (RBD) protein vaccination ...

Incyte (INCY) announced topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab, a humanized ...

Study patients had advanced metastatic disease and had received extensive prior therapy. A blinded, independent response evaluation committee identified eight complete and 26 partial responses, for an ...

Researchers have developed an antibody that prevents the activation of the Dickkopf 1-Cytoskeleton-associated protein 4 (DKK1-CKAP4) pathway, which is important for tumor growth in several cancers, ...

Flow cytometry enables researchers to label proteins of interest using fluorophore-conjugated antibodies and other fluorochromes. Much like immunohistochemistry, which produces two- or ...

Due to advancements in genetic engineering, small animal models are continuing to change in response to market needs. Model developers strive to better reflect the role of this important asset in both ...

Why do 80 to 90% of people infected with COVID-19 experience only mild cases while 10 to 20% face more severe or life-threatening symptoms? Researchers in the lab of Yale’s Richard Flavell decided to ...